U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H23F2NO2
Molecular Weight 371.4203
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LENPERONE

SMILES

FC1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)C(=O)C3=CC=C(F)C=C3

InChI

InChIKey=WCIBOXFOUGQLFC-UHFFFAOYSA-N
InChI=1S/C22H23F2NO2/c23-19-7-3-16(4-8-19)21(26)2-1-13-25-14-11-18(12-15-25)22(27)17-5-9-20(24)10-6-17/h3-10,18H,1-2,11-15H2

HIDE SMILES / InChI

Molecular Formula C22H23F2NO2
Molecular Weight 371.4203
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Lenperone (AHR 2277), or 4’-fluoro-4 [4-(p-fluorobenzoyl) piperidino] butyrophenone hydrochloride, is an antipsychotic compound which has been shown in preliminary experiments to possess those features essential for neuroleptic activity. Dopamine antagonist.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
4.3 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Lenperone

Doses

PubMed

Sample Use Guides

In Vivo Use Guide
50 hospitalized schizophrenic patients were treated 20-30 days with Lenperone. The therapeutic effective dose was 30-50 mg/day. The highest daily dosage was 90 mg.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Record UNII
13P4GX22ES
Record Status Validated (UNII)
Record Version